HealthDay - TUESDAY, Nov. 3 (HealthDay News) -- Reports about possible kidney problems, including renal failure, in people taking the diabetes drug exenatide (Byetta) have prompted changes to the drug's prescribing information, the U.S. Food and Drug Administration said Monday.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.